VKTX catalysts
Catalysts and events linked to VKTX, newest first.
DateCardAvg 5d
- 2026-10-19Viking Therapeutics Raises $575M in Equity and Convertibles for Phase 3 TrialsVKTX
- 2026-10-19Viking raises $575 million to fund obesity phase 3 trialsVKTX
- 2026-10-19Viking financing extends runway into 2028 for VK2735 trialsVKTX
- 2026-10-19Viking Therapeutics raises $575M via equity and convertible notesVKTX XBI
- 2026-10-19Viking Therapeutics Raises $575 Million to Fund Phase 3 Obesity TrialsLLY VKTX
- 2026-10-19Viking Therapeutics Raises $575 Million to Fund Phase 3 Obesity TrialsLLY VKTX
- 2026-10-19Viking raises $575 million to fund obesity pipeline trialsLLY VKTX
- 2026-10-19Viking raises $575 million to fund obesity trials through 2028LLY NVO VKTX
- 2026-10-19Viking Therapeutics Raises $575M in Equity and Convertibles for Phase 3 TrialsLLY VKTX
- 2026-10-19Viking financing extends runway into 2028 for VK2735 trialsVKTX
- 2026-10-19Viking raises $575 million to fund obesity phase 3 trialsLLY NVO VKTX
- 2026-10-19Viking financing keeps obesity trial runway open through 2028LLY VKTX
- 2026-10-11Viking Therapeutics Advances Oral Obesity Candidate VK2735 to Phase 3 Clinical TestingVKTX
- 2026-10-11Viking Therapeutics Advances Oral Obesity Candidate VK2735 Into Phase 3 TrialsLLY VKTX
- 2026-10-11Viking Therapeutics Advances Oral Obesity Drug VK2735 to Phase 3 Clinical TrialsLLY VKTX
- 2026-10-11Viking Therapeutics Advances Oral Obesity Candidate VK2735 to Phase 3 Clinical TestingLLY VKTX
- 2026-10-11Viking Therapeutics Advances Oral Obesity Drug VK2735 to Phase 3 TrialsLLY VKTX
- 2026-09-30Viking Reports 16% to 19% Weight Loss in VK2735 Obesity Clinical TrialVKTX
- 2026-09-30Viking Reports 16% to 19% Weight Loss in VK2735 Obesity Clinical TrialLLY VKTX
- 2026-09-30Viking Therapeutics Reports 16% to 19% Weight Loss for VK2735LLY VKTX
- 2026-06-12Viking Therapeutics Eyes $100 Target on Weight Loss Drug PotentialVKTX
- 2026-05-26Viking, AbbVie poised for obesity drug market growth.ABBV VKTX
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.